{
    "clinical_study": {
        "@rank": "90527", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This prospective observational study will evaluate the use in clinical practice, efficacy\n      and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients\n      with HER2-negative metastatic breast cancer. Data will be collected from eligible patients\n      for up to 2.5 years."
        }, 
        "brief_title": "An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Locally recurrent or metastatic breast cancer\n\n          -  No prior treatment for metastatic or locally recurrent disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n\n        Exclusion Criteria:\n\n          -  History or clinical evidence of brain metastases\n\n          -  Pregnancy\n\n          -  Uncontrolled hypertension  ( systolic > 150 mmHg and/or diastolic > 100 mmHg) or\n             clinically significant (i.e. active) cardiovascular disease\n\n          -  Major surgical procedure or significant traumatic injury within 28 days prior to\n             enrolment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "HER2-negative breast cancer patients in first-line treatment of metastatic disease"
            }
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661153", 
            "org_study_id": "ML25312"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Split", 
                        "country": "Croatia", 
                        "zip": "21000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varazdin", 
                        "country": "Croatia", 
                        "zip": "42000"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Croatia"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Croatia: Ministry of Health"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661153"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dosage/schedule/number of cycles of Avastin treatment in clinical practice", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}